NLS Pharma is the winner of the prestigious 9th Innovation Award as best Biotech company for 2017. Almost 300 firms took part in the event, with NLS Pharma taking 1st place for its advances and cutting-edge progress of the NLS-1 Compound.
Every year since 2009, the Innovation Prize rewards the most promising start-ups (<8 years old ) and the best academic research teams, which are currently developing a cutting edge project in the area of life sciences (Biotech, Medtech, m/e-health, diagnostics).
The Jury comprises several major Healthcare companies, pharmaceutical laboratories, biotechnology societies, and public institutions together with a law firm specialized in intellectual property. They have evaluated the submitted projects following these 5 criteria:
• The scientific quality of the innovation
• The quality of the team
• The strength of intellectual property
• The project feasibility
• The chances of success on the market
NLS Pharma is a Swiss-based biotech group focussing on treatments for attention deficit hyperactivity disorder (ADHD) sleep disorders, cognitive impairment, and other neurological disorders that remain largely underdiagnosed and for which unmet medical needs are significant. NLS Pharma has built a large portfolio of promising clinical- stage medicines being developed by an experienced team of proven experts in ADHD and sleep -related disorders and working closely with key opinion leaders. In May NLS announced positive clinical data from the Phase 2 study of its lead compound, NLS -1 (mazindol CR), as a potential novel option for the treatment of ADHD in adults.
Please login or sign up to comment.
Commenting guidelines